Neuregulin-1β Improves Uremic Cardiomyopathy and Renal Dysfunction in Rats

[Display omitted] •Uremic cardiomyopathy is characterized by LVH, diastolic dysfunction, and cardiac fibrosis, leading to HF.•Dysregulation of NRG-1β signaling is a known contributor to HF.•rhNRG-1β alleviated the progression of uremic cardiomyopathy and kidney dysfunction.•RhNRG-1β is a novel promising candidate in the prevention and therapy of uremic cardiomyopathy and renal dysfunction.•Further studies are needed to translate the beneficial effects of rhNRG-1β in patients with CKD. Chronic kidney disease is a global health problem affecting 10% to 12% of the population. Uremic cardiomyopathy is often characterized by left ventricular hypertrophy, fibrosis, and diastolic dysfunction. Dysregulation of neuregulin-1β signaling in the heart is a known contributor to heart failure. The systemically administered recombinant human neuregulin-1β for 10 days in our 5/6 nephrectomy–induced model of chronic kidney disease alleviated the progression of uremic cardiomyopathy and kidney dysfunction in type 4 cardiorenal syndrome. The currently presented positive preclinical data warrant clinical studies to confirm the beneficial effects of recombinant human neuregulin-1β in patients with chronic kidney disease.